Maxim Group reiterated their buy rating on shares of Beigene (NASDAQ:BGNE) in a report published on Tuesday morning, AnalystRatings.com reports. The brokerage currently has a $210.00 target price on the stock.
Several other research analysts have also recently issued reports on the company. Piper Jaffray Companies reissued a buy rating and issued a $230.00 target price (up from $200.00) on shares of Beigene in a research report on Friday, November 15th. UBS Group cut shares of Beigene from a buy rating to a neutral rating in a report on Tuesday, November 19th. Cowen lifted their price target on shares of Beigene from $170.00 to $225.00 and gave the stock an outperform rating in a research note on Wednesday, November 13th. Zacks Investment Research downgraded shares of Beigene from a strong-buy rating to a hold rating in a research report on Tuesday, November 5th. Finally, ValuEngine downgraded Beigene from a strong-buy rating to a buy rating in a research report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $208.00.
BGNE stock opened at $181.02 on Tuesday. The company has a market cap of $8.77 billion, a P/E ratio of -14.90 and a beta of 1.18. Beigene has a 1 year low of $108.00 and a 1 year high of $210.35. The company has a debt-to-equity ratio of 0.20, a current ratio of 5.40 and a quick ratio of 5.26. The stock’s fifty day moving average price is $183.97 and its 200-day moving average price is $142.47.
In other Beigene news, CFO Howard Liang sold 25,000 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $194.34, for a total value of $4,858,500.00. Following the completion of the sale, the chief financial officer now owns 122,317 shares in the company, valued at approximately $23,771,085.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CMO Jane Huang sold 1,500 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $194.49, for a total value of $291,735.00. Following the sale, the chief marketing officer now directly owns 291,667 shares in the company, valued at $56,726,314.83. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 73,704 shares of company stock worth $14,139,047. 10.70% of the stock is owned by company insiders.
Institutional investors have recently made changes to their positions in the company. Capital Investment Advisory Services LLC purchased a new stake in shares of Beigene during the second quarter worth about $26,000. Ladenburg Thalmann Financial Services Inc. boosted its stake in Beigene by 24.8% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 443 shares of the company’s stock valued at $55,000 after buying an additional 88 shares during the last quarter. Riverhead Capital Management LLC grew its holdings in Beigene by 28.6% during the 2nd quarter. Riverhead Capital Management LLC now owns 450 shares of the company’s stock valued at $56,000 after buying an additional 100 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new position in Beigene during the 3rd quarter valued at approximately $58,000. Finally, Tower Research Capital LLC TRC grew its holdings in Beigene by 1,500.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 592 shares of the company’s stock valued at $73,000 after buying an additional 555 shares in the last quarter.
Beigene Company Profile
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Read More: What is the Nikkei 225 index?
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.